Exceptional toxicity resistance

Stephen Sonis¹, Alessandro Villa², Joel Epstein^{3

4}

Affiliations

¹ Divisions of Oral Medicine and Dentistry, Brigham and Women's Hospital and the Dana-Farber Cancer Institute, Boston, MA, USA. ssonis@biomodels.com.
² Department of Orofacial Sciences, University of California at San Francisco, San Francisco, CA, USA.
³ City of Hope Comprehensive Center, Duarte, CA, USA.
⁴ Cedars-Sinai Medical System, Los Angeles, CA, USA.

Editorial

Stephen Sonis et al. Support Care Cancer. 2021 May.

. 2021 May;29(5):2263-2264.

doi: 10.1007/s00520-021-06065-4.

Stephen Sonis¹, Alessandro Villa², Joel Epstein^{3

4}

¹ Divisions of Oral Medicine and Dentistry, Brigham and Women's Hospital and the Dana-Farber Cancer Institute, Boston, MA, USA. ssonis@biomodels.com.
² Department of Orofacial Sciences, University of California at San Francisco, San Francisco, CA, USA.
³ City of Hope Comprehensive Center, Duarte, CA, USA.
⁴ Cedars-Sinai Medical System, Los Angeles, CA, USA.

No abstract available

References

1. Sroussi HY, Epstein JB, Bensadoun RJ, Saunders DP, Lalla RV, Migliorati CA, Heaivilin N, Zumsteg ZS (2017) Common oral complications of head and neck cancer radiation therapy: mucositis, infections, saliva change, fibrosis, sensory dysfunctions, dental caries, periodontal disease, and osteoradionecrosis. Cancer Med 6:2918–2931 - DOI
1. Villa A, Sonis S (2016) Toxicities associated with head and neck cancer treatment and oncology-related clinical trials. Curr Probl Cancer 40:244–257 - DOI
1. Tsimberidou AM, Said R, Staudt LM, Conley BA, Takebe N (2019) Defining, identifying, and understanding “exceptional responders” in oncology using the tools of precision medicine. Cancer J 25:296–299 - DOI
1. Conley BA, Staudt L, Takebe N, Wheeler DA, Wang L, Cardenas MF, Korchina V, Zenklusen JC, McShane LM, Tricoli JV, Williams PM, Lubensky I, O’Sullivan-Coyne G, Kohn E, Little RF, White J, Malik S, Harris LN, Mann B, Weil C, Tarnuzzer R, Karlovich C, Rodgers B, Shankar L, Jacobs PM, Nolan T, Berryman SM, Gastier-Foster J, Bowen J, Leraas K, Shen H, Laird PW, Esteller M, Miller V, Johnson A, Edmondson EF, Giordano TJ, Kim B, Ivy SP (2021) The exceptional responders initiative: feasibility of a national cancer institute pilot study. J Natl Cancer Inst 113:27–37 - DOI
1. Nishikawa G, Luo J, Prasad V (2018) A comprehensive review of exceptional responders to anticancer drugs in the biomedical literature. Eur J Cancer 101:143–151 - DOI